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We have shown that polyamide nucleic acids (PNAs) targeted to the PBS (PNAPBS) and A-loop (PNAA-loop) sequences, when transfected into
cells, inhibit HIV-1 replication by blocking the initiation of reverse transcription via destabilizing tRNA3
Lys primer from the viral genome. Here we
demonstrate that both PNAPBS and PNAA-loop conjugated with the membrane-transducing peptide (MTD) vectors penetratin and Tat are rapidly
taken up by cells and inhibit HIV-1 replication. Moreover, MTD peptide conjugates of PNAPBS and PNAA-loop displayed potent virucidal activity
against HIV-1. Brief exposure of HIV-1 virions to these conjugates rendered them noninfectious. The IC50 values for virucidal activity were in the
range of ∼50 nM; IC50 values for inhibition of HIV-1 replication/infection were 0.5 μM–0.7 μM. The virucidal property of these conjugates
suggests that a cocktail of anti-HIV-1 PNA–MTD peptide conjugates targeting critical regions of the HIV-1 genome could serve as a prophylactic
agent for inactivating HIV-1 virions after exposure to HIV-1.
© 2007 Elsevier Inc. All rights reserved.Keywords: HIV-1; Polyamide nucleic acid; Membrane transducing peptides; PNA–peptide conjugate; Primer binding site; Virucidal activity; A-loopIntroduction
Despite the best efforts of the research community and
pharmaceutical companies all over the world, the AIDS
pandemic continues to grow. Developing vaccines for human
immunodeficiency virus type-1 (HIV-1), the etiological agent of
AIDS, is predicted to be the best means of preventing the spread
of this virus. However, the recent failure of an experimental
vaccine based on recombinant gp-120 protein in phase III trials
(Cohen, 2003) and the slow progress of other vaccine trials
(Letvin, 2005) portends that development of an effectiveAbbreviations: PBS, Primer-binding site; HIV-1, Human immunodeficiency
virus type-1; RT, Reverse transcriptase; PNA, Polyamide nucleic acid; dNTP,
Deoxynucleoside triphosphate; DMF, Dimethylformamide; TFA, Trifluoroace-
tic acid; MTD, Membrane transducing; NMP, N-methyl pyrrolidinone; DCM,
Dichloromethane; Tyr, Tyrosine.
⁎ Corresponding author. Fax: +1 973 972 5594.
E-mail address: Pandey@umdnj.edu (V.N. Pandey).
0042-6822/$ - see front matter © 2007 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2007.01.016vaccine will take longer than anticipated. While highly active
antiretroviral therapy (HAART) has demonstrated success in
treating AIDS patients, it is not curative. Most patients even-
tually develop resistance to HAART because of the selection of
genetic mutations in the virus results in resistance to drugs.
HAART also does not help prevent the spread of HIV-1 infec-
tions, a goal that is essential to for control the AIDS pandemic.
Because the majority of new infections occur through
sexual contacts (http://www.cdc.gov/hiv/stats/2003Surveillance
Report/table3.htm), new strategies, including the widespread
use of topical formulations of virucidal agents, need to be
rapidly deployed. Enfuvirtide (T-20) is the only FDA-approved
inhibitor of HIV-1 entry in clinical use (Kilby et al., 1998). This
drug is reported to have synergistic efficacy in the presence of
PRO 542, another potent entry inhibitor (Jacobson et al., 2004;
Nagashima et al., 2001). Recently, it has been suggested that
the N-terminal 33-amino-acid long sequence of gp120 also acts
as a fusion inhibitor (Gerber et al., 2004). It also has been
suggested that various surfactants have anti-HIV-1 virucidal
Fig. 1. Binding affinity of PNAPBS–MTD peptide conjugates to their target
sequences. The gel mobility shift assay was performed to assess the binding
affinity of the PNAPBS–MTD peptide conjugates in comparison to that of
unconjugated naked PNAPBS control. PNAPBS–Penetratin, PNAPBS–Tat, and
unconjugated naked PNAPBS were incubated at varying concentrations with
10 nM of internally 32P-labeled U5-PBS RNA transcript in the binding buffer for
30 min at room temperature. The incubated samples were then loaded on a pre-
run 8% native polyacrylamide gel. The RNA: PNA complex was resolved and
separated from free RNA by running at 150 V for 4 h. Lane 1 represents U5-PBS
RNA alone; lanes 2 to 7 represent increasing amounts of PNAPBS or its MTD
conjugates, ranging through 2.5, 5.0, 7.5, 10, 15, and 20 nM. (A) PNAPBS alone;
(B) PNAPBS–Penetratin; (C) PNAPBS–Tat.
92 S. Tripathi et al. / Virology 363 (2007) 91–103activity (Bestman-Smith et al., 2001). Nonoxynol-9, a well-
known spermicide, has been reported to inactivate HIV-1 in
vitro (Bourinbaiar and Lee-Huang, 1994). Unfortunately,
studies have revealed that after prolonged and frequent use
of Nonoxynol-9, lesions and perforations may develop in the
vaginal surface, rendering women who use this ointment more
susceptible to HIV-1 infection (Van Damme et al., 2002).
Synthesis of proviral DNA, an essential step in the life cycle
of HIV-1, occurs exclusively in the multi-step process of
reverse transcription. The 5′(R-U5-PBS) untranslated region of
HIV-1 viral genome (1–333 nt) is a highly conserved region
containing several immutable stretches. In the 5′-untranslated
region, the 18-mer stretch from 183–201 nucleotides is known
as a primer binding site (PBS). Because the 3′ terminals 18-
nucleotides of the cellular tRNA3
Lys are complementary to the
PBS, they prime onto the PBS and initiate the reverse-
transcriptase-catalyzed synthesis of proviral DNA. This unique
feature of immutable PBS makes it as a potentially useful
therapeutic target.
Another important site is the A-loop region, which is located
upstream to the PBS-region from 168–173 nt. This region is
responsible for the selection of and, thereafter, the exclusive
interaction with the cellular tRNA3
Lys. Although several cellular
tRNAs are packaged along tRNA3
Lys, HIV-1 is quite conserva-
tive in using tRNA3
Lys as primer for the initiation of reverse
transcription (Mak and Kleiman, 1997; Isel et al., 1995).
Therefore, sequestering the A-loop region and making it
unavailable for interaction with tRNA3
Lys will ultimately
interfere with the selection and binding of the initiating primer.
Polyamide nucleic acids (PNAs), a novel class of DNA
analogs, were first synthesized as potent antisense agents; these
analogs are comprised of a 2-aminoethyl glycine backbone with
the purine and pyrimidine bases attached via an ethylene linker
(Nielsen et al., 1991). Being a structural, but not chemical
mimic of the sugar phosphate backbone of DNA/RNA, PNAs
are not recognized as substrates for cellular nucleases and
proteases (Demidov et al., 1994). We have demonstrated that
the PBS sequence is a unique target that can be used to halt viral
replication by sequestering this region and blocking the
initiation of reverse transcription using complementary naked
PNA (Lee et al., 1998; Kaushik and Pandey, 2002)We have also
shown that a 15-mer PNA targeted to the A-loop sequence can
specifically sequester the target sequence and inhibit the
initiation of reverse transcription (Kaushik et al., 2001). The
major drawback associated with PNAs as antisense agents is
their low level of uptake by cells. The peptide backbone confers
a hydrophobic character and a net neutral charge to PNAs,
making them unlikely candidates for cellular uptake. Many
different approaches, including microinjection (Taylor et al.,
1997), PNA-DNA co-transfection (Nulf and Corey, 2004),
electroporation (Shammas et al., 2004) and conjugation with
neamine (Riguet et al., 2004), have been taken in attempts to
overcome this obstacle. In the present study, we have addressed
the bio-delivery issue by conjugating 16-mer PNAs comple-
mentary to the primer-binding site and the A-loop region of the
viral genome with two different peptide sequences: penetratin, a
16-amino acid antennapedia peptide derived from the third helixof the homeodomain and Tat peptide, a 13-amino acid peptide
comprising 48–60 residues of the human immunodeficiency
virus-1 Tat protein. These anti HIV-1 PNA-peptide conjugates
are efficiently internalized in the cells and exhibit virucidal as
well as antiviral activity in cell culture.
Results
Binding affinity of the PNAs remains unaltered when
conjugated with MTD peptides
PNAs form more stable PNA: RNA and PNA: DNA hybrids,
as confirmed by the finding of relatively much higher Tms than
those of their DNA: RNA and DNA: DNA homologues (Nielsen
et al., 1991; Lee et al., 1998). To examine the influence of
conjugated MTD peptides on the binding affinity of PNAs for
their target sequence, we performed a gel mobility shift assay by
incubating U5-PBS RNA with increasing concentrations of
PNAPBS–Penetratin and PNAPBS–Tat. At a 1:4 molar ratio of
U5-PBS to PNA–peptide conjugate, the shift was visible; at an
equimolar ratio, a >90% shift was obtained (Fig. 1). Similar
results were obtained with PNAA-loop–MTD peptide conjugates
(results not shown). There is no apparent difference between the
binding pattern of PNA alone and that of the PNA–MTDpeptide
conjugates, confirming that the affinity of the PNA remains
unaltered even after conjugation with the MTD peptides.
PNA–MTD peptide conjugates are efficiently taken up by the
cell
It is expected that the extent of cellular uptake of PNA cargo
mediated by MTD peptides may depend on the solubility of
PNA, which is mainly governed by its sequence and composi-
tion. A pyrimidine base content of >40% enhances the solubility
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their solubility. Pyrimidine bases in PNAPBS constitute 50%,
while those of PNAA-loop constitute 60% of total bases,
rendering them highly soluble in buffer solution under
physiological conditions. The conjugation of PNAs with highly
polar MTD peptides may also enhance the solubility of even
those PNAs that are less soluble in polar solvents. We examined
the cellular uptake of these PNAs conjugated to either Penetratin
or Tat peptide in CEM cells, using flow cytometry. The cells
were incubated for 1 min with increasing concentrations of the
fluorescein-labeled PNAPBS–peptide conjugates at 4 °C and
37 °C. After washing the cells with phosphate-buffered saline
and resuspending them in RPMI medium with 2% fetal calf
serum, flow cytometry analysis was performed. Fig. 2 shows
a representative result for the experiments obtained with
PNAPBS–MTD peptide conjugates. The uptake pattern of
PNAPBS–Penetratin was found to be rapid and, at a 300-nM
concentration, almost 100% of the cells were positive for
fluorescein. While the uptake pattern of PNAPBS–Tat was found
to increase linearly, only 80% of the cells were fluorescence-
positive at 500 nM (Fig. 2, Panels a and b). Similar results were
obtained with PNAA-loop–MTD peptide conjugates (data not
shown). To rule out any artifacts due to nonspecific adherence of
the fluorescein-tagged PNA–MTD peptide conjugates to the
outer surface of the cell membrane, the cells were further treatedFig. 2. Flow cytometry analysis of uptake of anti-HIV-1 PNAPBS–MTD peptide con
PNAPBS–Tat and PNAPBS–Penetratin for 1 min at 4 °C and 37 °C. After washing th
RPMI media with 2% FCS. (a) Flow cytometry data at 37 °C in the presence of prop
concentration of PNAPBS–MTD peptide conjugates; (c) The flow cytometry data afte
treatment.with 0.01% trypsin for 10 min, washed, and examined by flow
cytometry. It was observed that trypsin treatment resulted in only
a marginal 5–8% reduction in the fluorescence of cells, while the
overall uptake pattern remained unchanged (Fig. 2, Panels c and
d). For visual demonstration of the uptake and cellular
localization of PNA–peptide conjugates, the cells incubated
with the flu-PNAPBS–peptide conjugate were examined by
fluorescence microscopy. As shown in Fig. 3, the PNA–
Penetratin conjugate is efficiently internalized and localized in
the cytoplasm, the site for reverse transcriptase process.
Uptake kinetic studies suggest cooperative interaction
The mechanism by which Penetratin and Tat peptide enter
the mammalian cells is still not entirely clear. The uptake
mechanism for Penetratin and Tat peptides has been shown to
occur via an energy-independent nonendocytotic process, as
these peptides are efficiently taken up by cells even at 4 °C
(Derossi et al., 1998; Vives et al., 1997). Neither sequence-
specific inversion nor synthesis with D-amino acids alters the
cellular uptake of Antennapedia (Penetratin) or Tat, indicating
that interaction with chiral receptors is not the major pathway of
entry into cells (Derossi et al., 1996). Recent reports have
contradicted earlier findings regarding the uptake pattern of Tat
peptide, suggesting that a specialized form of endocytosis has ajugates. CEM cells (0.5×106) were incubated with increasing concentrations of
oroughly with phosphate-buffered saline solution, the cells were resuspended in
idium iodide; (b) The percent of FITC-uptake per 104 cells as a function of the
r trypsin treatment for 10 min; (d) The percent uptake per 104 cells after trypsin
Fig. 3. Fluorescence microscopy of the uptake of fluorescein-labeled PNAPBS–Penetratin in CEM cells. The cells were incubated with fluorescein-labeled PNAPBS–
Penetratin conjugate for 30 min and then fixed and stained as described in Materials and methods. An aliquot of the cells was examined using the ZEISS Axiovert
200 M microscope. Panel (a)—nucleus stained with DAPI; Panel (b)—cell cytoplasm showing bright green fluorescence of the fluorescent PNA; Panel (c)—nuclei
merged with cell cytoplasm.
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2005). Flow cytometry revealed that a similar pattern of uptake
was exhibited by PNA–MTD peptide conjugates. Because flow
cytometry of uptake provides only qualitative data, we also used
I125-labeled PNA–MTD peptide conjugates to determine the
uptake kinetics of PNA–MTD peptide conjugates. The PNA
moiety of the conjugate was tagged with radioiodine via a lone
Tyr residue at its C-terminus, while MTD peptide devoid of Tyr
residue remained attached at the N-terminus of PNA. The CEM
cells were incubated with varying concentrations of individual
radiolabeled PNA–MTD peptide conjugates for 30 s at room
temperature followed by filtration and washing of the glass-fiber
(GF-B, Schleicher and Schuell, Keene, NH) filters. Based on theFig. 4. Uptake kinetics of PNAPBS–MTD peptide conjugates: CEM cells (0.5×10
conjugate for 30 s at room temperature. The cells were filtered on glass fiber filters (G
was counted in a gamma counter. The cooperative index ([S]0.9/[S]0.1) was determined
shown in the left panel. In the right panel, the log of the conjugate concentration was
(nH), as well as [S]0.5, denoting the concentration of conjugate at which uptake velospecific radioactivity of radioiodinated conjugates, the actual
conjugate concentration internalized by the cells was deter-
mined by measuring the radioactivity in the cells by gamma
counting. We observed that cellular uptake of individual anti-
HIV-1 PNA–MTD peptide conjugates displayed a sigmoidal
curve, suggesting cooperative interaction between the conju-
gates and the cell membrane. The cooperative index was
obtained from a Hill plot of the uptake data (Fig. 4). This index
is the ratio of substrate concentration ([S]0.9/[S]0.1) at 0.9Vmax
and 0.1Vmax of uptake, and is a measure of the amount of
conjugate that would be required to increase the uptake velocity
from 0.1Vmax to 0.9Vmax. The cooperative indices for PNAPBS–
Penetratin and PNAPBS–Tat were 6.85 and 8.0, respectively,6) were incubated with either I125-labeled PNAPBS–Penetratin or PNAPBS–Tat
F-B) and washed with phosphate-buffered saline. The incorporated radioactivity
by plotting the uptake of conjugate against the log of conjugate concentration as
plotted against log V/Vmax−V to obtain a Hill plot. The value for Hill coefficient
city is 0.5Vmax, was determined from the slope of the Hill plot.
Fig. 5. The antiviral efficacy of PNAPBS– and PNAA-loop–MTD peptide
conjugates: T lymphocyte cells were first infected with pseudo-HIV-1 virions for
2 h in the presence of varying concentrations of either PNAPBS–MTD peptide
conjugates (a) or PNAA-loop–MTD conjugates (b). Unconjugated PNA and
peptides alone were included as control. The infected cells were further grown in
the presence of increasing amounts of respective PNA–MTD conjugates for
48 h. The cells were harvested, washed, and lysed. An aliquot of the cell lysate
was examined for luciferase activity and the percentage of inhibition of
luciferase expression in treated cells was determined with respect to that in
untreated control. Median-effect plots and dose–effect curves were calculated.
The dose median values (IC50) for individual PNAPBS– and PNAA-Loop–MTD
peptide conjugates are indicated. Antiviral efficacy was also examined in PHA
stimulated peripheral blood mononuclear lymphocyte (PBMC) cells using
PNAPBS–peptides (c) and the infected cells were grown for 7 days before
harvesting. The cell lysate was examined for luciferase activity as described
above. Naked PNA and peptide alone had no effect on antiviral efficacy as
naked PNA are found to be incompetent of cellular uptake and presence of
peptide had no effect on viral infectivity. In both these cases the levels of
luciferase expression was found to be similar to the untreated virions, therefore
no values can be generated to put in the CalcuSyn software.
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easily achieved by increasing their respective concentrations by
6.85- and 8.0-fold, respectively.
A Hill plot of the uptake was calculated to determine the nH
values for individual PNA–MTD peptide conjugates. The [S]0.5
and nH values for individual PNA–MTD peptide conjugates
were determined from this plot, where [S]0.5 value indicates the
concentration of the conjugate at which uptake velocity is 0.5 of
Vmax. The [S]0.5 values were, respectively, 900 nM and 950 nM
for PNAPBS–Penetratin and PNAPBS–Tat. The values of the Hill
coefficient (nH) were less than 1 for both of the PNA–MTD
peptides, suggesting that the cooperativity of uptake is not due
to multiple interaction sites on the cell membrane. In an uptake
system following sigmoidal kinetics, the velocity of uptake can
be significantly enhanced by a small increase in substrate; in
contrast, an uptake system following hyperbolic kinetics
requires a large amount of substrate to achieve a similar
increase in velocity. The sigmoidal kinetics we observed by the
PNA–MTD conjugates can be viewed as favorable criteria for
their qualification as potential virucidal agents.
PNA–MTD peptide conjugates show efficient anti-HIV-1
activity
We have shown that anti-HIV-1 PNAs targeting the PBS
region, as well as the A-loop region upstream to the PBS region
in the 5′-UTR of the HIV-1 genome, inhibit HIV-1 replication
when transfected into cells (Kaushik and Pandey, 2002;
Kaushik et al., 2001). Exploring means of improving the bio-
delivery of anti-HIV PNAs, we conjugated them with
membrane-transducing peptides via a disulfide bond. We
conjugated Penetratin, a 16-amino-acid homeodomain protein,
and Tat, a 13-amino-acid protein comprising 48–60 amino acids
of the HIV-1 Tat peptide, with both the anti-PBS and anti-A-
loop PNAs. We then examined the efficiency of PNA–peptide
conjugates in inhibiting the replication of HIV-1. For this
purpose activated PBMC as well as CEM T-lymphocyte cells
infected with pseudo HIV-1 virions carrying firefly luciferase
reporter gene were grown in the presence of increasing
concentrations of PNA–peptide conjugates. The CEM cells
were harvested after 48 h while PBMC cells were harvested
after 7 days. The cells were washed once with phosphate-
buffered saline, then lysed. After normalization of the protein
content, an aliquot of the extract was analyzed for quantitative
levels of luciferase expression to evaluate the level of HIV-1
infection. Median dose values (IC50) were calculated by plotting
concentration versus percentage inhibition of luciferase expres-
sion. The median dose effect values (IC50) of PNAPBS–MTD
conjugates were in the range of 0.28–0.32 μM with PBMC
while 0.53 to 0.55 μMwith CEM cells. Similar results were also
obtained with PNAA-loop–MTD peptide conjugates (Fig. 5,
Table 1A).
PNA–MTD peptide conjugates as potent virucidal agents
We found that PNA–MTD peptides targeting the PBS and
A-loop sequences were efficient in inhibiting the HIV-1
Table 1A
Antiviral and virucidal activity of PNA–peptide conjugates targeting PBS and






Inhibitory effect on HIV
replication IC50 [nM]
CEM cells PBMC
PNAA-loop–Penetratin 56 745 ND
PNAA-loop–Tat 47 726 ND
PNAPBS–Penetratin 49 557 280
PNAPBS–Tat 50 532 320
The antiviral and virucidal activities of the conjugates were assessed in complete
RPMI medium containing 10% fetal calf serum as described in Materials and
methods, The median effective doses (IC50) of these conjugates were calculated
from data shown in Figs. 4 and 5a,b.
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jugate are able to block HIV-1 infection by inactivating the
virion particles (virucidal) or whether they have an antiviral
effect only after their entry into the cell. We evaluated the
virucidal activity of these conjugates by a brief exposure of
purified HIV-1 virions to increasing concentrations of
individual PNA–MTD conjugates. We separated the virion
particles from the free conjugates by ultracentrifugation and
used them to infect lymphocytes. After growing the infected
lymphocytes for 48 h, we examined the cell lysates for
luciferase activity. The extent of luciferase activity was
inhibited with the increasing concentrations of PNA–MTD
conjugates with which virion particles were incubated. The
median effective doses (IC50) were ≈50 nM for both PNAPBS–
Tat and PNAPBS–Penetratin; those for PNAA-loop–Tat and
PNAA-loop–Penetratin were 47 nM and 56 nM, respectively
(Figs. 6a, b, Table 1A).
Effect of increasing serum concentration on the virucidal
activity of the conjugate: The observed virucidal activity of anti-
HIV-1 PNA–peptide conjugate shown as above was noted in
the complete RPMI medium containing 10% fetal calf serum.
Since infectious HIV-1 virions circulate and survive in the blood
serum, we also examined virucidal activity at higher serum
concentration ranging from 20% to 100% serum. It was
observed that increasing serum concentration has no significant
effect on the virucidal activity of the conjugate (Figs. 6c, d, and
Table 1B).
Inhibition of endogenous reverse transcription in HIV-1 virions
pretreated with PNA–peptide conjugates
Among retroviruses, the synthesis of proviral DNA occurs
by a multistep reverse transcription process. HIV-1 exclusively
uses tRNA3
Lys as the initiating primer as it anneals among the
naturally occurring cellular tRNAs at the PBS and the upstream
A-loop region in the 5′-UTR (Wakefield et al., 1995). We have
shown that both unconjugated PNAPBS and PNAA-loop effi-
ciently displace tRNA3
Lys–U5-PBS complex and inhibit the
initiation of reverse transcription (Kaushik and Pandey, 2002;
Kaushik et al., 2001). Since HIV-1 virions pretreated with
PNAPBS and PNAA-loop–MTD peptide conjugates were ren-
dered noninfectious in the present study, we postulated thatthese conjugates might be readily internalized into the virion
particles and bind to their target sequences on the viral genome.
To test this hypothesis, we ultracentrifuged virion particles
pretreated with varying concentrations of individual conjugates
through a 20% sucrose cushion, then disrupted the virion pellets
and examined them for endogenous reverse transcription. As
shown in Fig. 7, the initiation of endogenous reverse trans-
cription was completely blocked in virion particles pretreated
with both PNAPBS–peptide and PNAA-loop–peptide conjugates.
The virions untreated or treated with scrambled PNA–MTD
conjugates (CGG-ACT-AAG-TCC-ATT-GC) were also
included as controls. In both the cases the reverse transcription
products were larger than 490 nucleotides, indicating that strand
transfer had taken place after synthesis of (−) strand strong-stop
DNA, suggesting that the conjugates permeated the virus
envelope and bound to their cognate sequences on the viral
RNA, thus preventing the initiation of the reverse transcription.
It can be argued that the conjugates may have tightly attached to
the external surface of the viral envelope and bound to the target
only after the virions were disrupted. However, this possibility
is ruled out by the fact that virions envelope derived from cell
membrane, permeation of conjugates into virion particles would
likely occur by a mechanism similar to that of cellular uptake,
which was not affected by trypsin treatment after incubation
with fluorescein-labeled conjugate (data not shown). Further,
the naked PNA alone when incubated with virion particles had
no influence on endogenous RT activity (data not shown). The
use of I125-labeled PNATAR–Transportan conjugate showed
that, after incubation with virions, the radioactive PNA
conjugate co-sedimented with the virion particles (Chaubey
et al., 2005). That finding indicates that virions are highly
vulnerable to treatment with targeted anti-HIV-1 PNA–MTD
peptide conjugates as judged by loss of their infectivity upon
exposure to individual conjugates, indicating the potential of
this class of compounds as potent virucidal agents against
HIV-1.
PNA–peptide conjugates have no toxic effect on cellular
proliferation. Incorporation of [3H] thymidine was studied to
examine the effect of PNA–Speptide conjugates on cellular
proliferation. The cells were grown in presence of varying
concentrations of PNA–peptide conjugates (1–10 μM) and
assayed for the incorporation of [3H] thymidine in the cellular
DNA. The results shown in Fig. 8 suggest that PNA–peptide
conjugates are well tolerated and therefore not toxic to the cells
at the indicated concentrations.
Discussion
In pursuit of a new microbicidal/virucidal agent for use
against HIV-1, we have targeted various conserved regions in the
U5-PBS region of viral RNA. In the life cycle of retroviruses, a
family to which HIV-1 belongs, reverse transcription has a
pivotal function. HIV-1 uses tRNA3
Lys, one of several cellular
tRNAs packaged during virion assembly, exclusively as primer
for the initiation of the reverse transcription of minus-strand
strong-stop DNA (Mak and Kleiman, 1997). By virtue of
complementarity, 18-nucleotides of the 3′-terminal of tRNA3
Lys
Fig. 6. Dose–effect curve (IC50) of virucidal activity of individual PNAPBS– and PNAA-loop–MTD peptide conjugates: The HIV-1 virions (equivalent to 100 ng of p24)
were first incubated with increasing concentrations of individual PNA–MTD peptide conjugates for 2 h in complete RPMI medium containing 10% FCS. Naked PNA
and peptides alone were included as control. The pretreated virions were then used to infect the CEM cells. The infected cells were grown for 48 h and the extent of
infection was determined by measuring the levels of luciferase reporter enzyme in cell lysate. Dose–effect curves and median-effect plots (IC50) were calculated.
Dose–effect curves for virucidal activity of individual PNAA-Loop–MTD peptide conjugate (a), and individual PNAPBS–MTD peptide conjugates in the presence of
10% FCS (b), 60% FCS (c) and 100% FCS (d). No values could be generated for naked PNA and peptide alone.
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U5 region of the 5′-LTR from 183–201 of the viral RNA
genome. Inducing mutations in the primer binding site to make it
complementary to tRNAHis transiently results in the production
of infectious virus that reverts back to use tRNA3
Lys in in-vitro
cell culture (Wakefield and Morrow, 1996; Zhang et al., 1998).
This set of experiments demonstrates that HIV-1 PBS, given
appropriate mutational changes, can use tRNAIle and tRNAHis as
primers. However, the appearance of viruses may be delayed as
compared to that of the wild type one produced while using
tRNA3
Lys (Wakefield et al., 1995). When non-tRNA3
Lys primers
are used for reverse transcription, defective replication patterns
are seen. Also, the rates of virus production using tRNAHis and
tRNAMet are 1/10 and 1/100, respectively, as compared to
viruses produced using tRNA3
Lys (Wei et al., 2005). The viruses
produced in this way show varied capacities for infectivity, as thevirions using tRNAMet are produced at 1/100 that of wild type,
while virions made using tRNAHis do not produce virions at all.
In U5-PBS, another region also reportedly has a crucial function
in the selection and stabilization of tRNA3
Lys. That region on
viral genome is the A-loop region (nucleotides 168–173), so
named because it comprises four consecutive “A” located
upstream to the U5 PBS region. This A-rich loop anneals with
the U-rich region of tRNA3
Lys, thus providing further selectivity
and stability of the tRNA3
Lys primer (Isel et al., 1995).
These observations suggest that highly conserved and
immutable PBS and A-loop sequences in the U5-PBS region
may be ideal targets for intervention by HIV-1 replication. Han
et al. (2004) have reported that transfection of a 21-nucleotide
siRNA targeted to the PBS site exerts an inhibitory effect on
HIV-1 production after HIV-1 infection. In contrast, targeting
gag mRNA using siRNA has a transient effect on virus
Table 1B




% of fetal calf serum
20 40 60 80 100
Virucidal activity (IC50 in nM)
PNAPBS–Penetratin 50 58 54 58 50
PNAPBS–Tat 52 58 58 59 60
The infectious HIV-1 virions were first preincubated with different concentra-
tion of PNAPBS–peptide conjugates in the presence of 20–100% fetal calf serum
and their infectivity was then assessed in CEM cells as described in Materials
and methods. The IC50 for virucidal activity at different serum concentrations
were calculated from dose–effect curves and median-effect plots as described in
Materials and methods. Representative plots at 60% and 100% serum
concentrations are shown in Figs. 6c and d.
Fig. 7. Endogenous RT activity of HIV-1 virions after brief exposure to
individual PNAPBS– and PNAA-loop–MTD peptide conjugates. The virion
particles pretreated with individual PNA–MTD peptide conjugates at 250 nM
(lane 1) and 500 nM (lane 2) concentrations were centrifuged at 100,000 g
through a 20% sucrose cushion to separate them from free PNA–MTD peptide
conjugates. The scrambled PNA–MTD peptide conjugate was also used
separately as the negative control. The virion pellets were disrupted in disruption
buffer. Aliquots of the disrupted virions were examined for endogenous RT
activity. The reaction products, after phenol–chloroform extraction and ethanol
precipitation, were resolved on 6% denaturing polyacrylamide gel. The control
(C) represents the endogenous RT activity in untreated disrupted HIV-1 virions
showing products resulting from the strand transfer step. The lane marked M
represents the DNA markers corresponding to 90, 250, and 490 bases.
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effect of siRNA and reverts to normal. However, similarly
targeting the A-loop region with siRNA showed no consistent
decrease in virus production (Han et al., 2004). In contrast,
targeting the A-loop region with PNAA-loop–MTD peptide
conjugates resulted in decreased HIV-1 replication/infection. It
is possible that once the PNA sequence recognizes and binds to
its target, the secondary structure of RNA is lost, resulting in
inability of the A-loop to provide an annealing site to tRNA3
Lys.
Besides these points, we found that the PNA bound upstream of
the PBS sequences resulted in complete blockage of reverse
transcription (Fig. 7). It has been reported that PNA is able to
invade double-stranded DNA and bind to its target, displacing
the second strand into a D-loop structure (Nielsen et al., 1991).
Earlier, we demonstrated that a 16-mer polyamide nucleic
acid complementary to the 5 nucleotides of the PBS and the 11
upstream sequences spanning to the stem region of the A-loop
inhibits virus replication in cell culture (Kaushik and Pandey,
2002). Although we noted strong antiviral efficacy when naked
PNAPBS was transfected into cells, issues about bio-delivery
needed to be solved to achieve the practical potential of this
approach. In the present study, we have demonstrated that both
PNAPBS and PNAA-loop, after conjugation with membrane-
transducing peptides, are rapidly taken up by cells when added
into the culture medium. Further, we found that cellular uptake
of these PNA–MTD peptide conjugates was neither due to
endocytosis nor receptor-mediated, since identical uptake
patterns were observed at both physiological and reduced
temperatures (Fig. 2). This finding was consistent with our
earlier observations (Tripathi et al., 2005; Chaubey et al., 2005)
that uptake of another anti-HIV-1 PNA–MTD peptide con-
jugate targeted to HIV-1 LTR was not affected after the
treatment of cells with phenylarsine oxide, which selectively
modifies and modulates their receptor functions.
The FACS studies using PNA–Penetratin conjugates showed
rapid and saturating cellular uptake, with 98% fluorescence-
positive cells at subnanomolar concentration after 1 min of
exposure to the fluorescence-labeled PNA–peptide conjugates.
Our similar studies with PNA–Tat peptide were equally
promising, showing almost 80% fluorescence-positive cells.
Although the mode of entry of cell penetrating peptides (CPPs)remains unclear, since conflicting description of internalization
process vary from energy independent cell penetration of
membrane to endocytotic uptake. Some recent reports do
suggest their entry via endosomal pathway (El-Andaloussi et
al., 2005). More recent reports further suggest that mode of
internalization of CPP is influenced by cargo attached to it
(Tunnemann et al., 2006). The unconjugated Tat peptide has
been shown to be taken up by endocytosis while in presence of a
counteranion such as pyrenebutyrate it is taken up by direct
membrane translocation resulting in diffuse cytosolic distribu-
tion (Takeuchi et al., 2006).We have earlier shown that uptake of
PNATAR–Transportan conjugate is temperature independent and
not affected by phenylarsine treatment of the cells suggesting
non-involvement of endocytosis or receptor mediated inter-
nalization of this conjugate (Chaubey et al., 2005). In the present
studies, we noted similar uptake pattern for both PNA–
Penetratin and PNA–Tat conjugates. These observations for
Fig. 9. The sequences of different PNA–peptide conjugates used.
Fig. 8. Effect of PNA–peptide conjugate on [3H] thymidine incorporation into
cellular DNA in CEM cells: CEM cells were grown in the absence and presence
of PNAPBS–Penetratin (1 μM, 5 μM and 10 μM). The culture media was
supplemented with 10 μCi of [methyl-3H] Thymidine/ml. The cells were
harvested at 6, 12, 18, 24, 48, 72 and 96 h. The cells were assayed for the amount
of [3H]-Thymidine (TdR) incorporated into DNA by using TCA precipitation
assay.
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the uptake of unconjugated Tat peptide which is ATP and
temperature dependent indicating the involvement of endocy-
tosis mechanism (Richard et al., 2003, 2005). Therefore it is
possible that uptake of CPP alone and in conjugated form may
widely differ and may be influenced by the nature of the cargo it
is carrying. The uptake kinetics data for PNA–peptide conju-
gates suggest a cooperative binding model, as the conjugates
follow a sigmoidal pathway. The cooperative indices ([S]0.9/
[S]0.1) for PNAPBS–Penetratin and PNAPBS–Tat were 6.85 and
8.0, respectively, indicating that to achieve the uptake velocity
from 0.1Vmax to 0.9Vmax, only an 6.85-fold increase in the
concentration of PNAPBS–Penetratin or an 8.0-fold increase in
the concentration of PNAPBS–Tat would be required. For a
compound following a hyperbolic uptake pathway, a 90-fold
increase in the substrate concentration would be required to
achieve a similar increase in Vmax from 0.1 to 0.9. Therefore, low
values for cooperative indices are extremely beneficial for a
compound to qualify as a drug.
All of the preceding observations suggest that PNA–peptide
conjugates targeted toward conserved sequences on the
regulatory U5-PBS region of viral RNA may be potential agents
for drug development. The IC50 values of these conjugates for
antiviral efficacy were in the range of 500–750 nM. The most
exciting observation was that these conjugates, besides display-
ing antiviral efficacy in cell culture, were potently virucidal
against HIV-1. Brief exposure of HIV-1 virions to these
conjugates rendered them noninfectious. The median effective
dose (IC50) values for virucidal activity of these PNA–peptide
conjugates was≈50 nM. The observed virucidal effect could be
the result of either disruption of the virion envelope by the
conjugates or internalization of the conjugates into the virion
particles (Chaubey et al., 2005). We demonstrated that brief
exposure of cell-free HIV-1 virions to these conjugates, followed
by the separation of virions from the free conjugate by
ultracentrifugation, resulted in complete blockage of endogen-
ous reverse transcription in the disrupted virion particles (Fig. 7).Similar inactivation of virion particles and inhibition of endo-
genous reverse transcription has been demonstrated by pretreat-
ment of HIV-1 virions with AZT-TP, a nucleoside reverse
transcriptase inhibitor and nevirapine in the presence of poly-
amines (Argyris et al., 2006). We believe that PNA–MTD
peptide conjugates represent a promising new class of com-
pounds and plan to pursue further investigation into their value
as topical antiviral/microbicidal agents.
Materials and methods
Design of PNA and peptide sequences
The PNAs were custom-synthesized by Applied Biosystems,
Bedford, MA. A 16-mer anti-PBS PNA sequence, CGCCACT-
GCTAGAGAT, was designed targeting five nucleotides of the
PBS sequences and 11 nucleotides upstream to PBS in the 5′-
nontranslated region of the viral genome. At the N-terminal of
the PNA sequences, a cysteine was covalently linked for further
conjugation with the peptide sequence using disulphide linkage.
For uptake kinetic studies, the sequence synthesis was started
with a tyrosine unit at the C-terminal, which was used for
labeling the sequence with I125 (Fig. 9). For cellular uptake
studies, we used fluorescein-labeled PNA. For targeting the A-
rich region upstream of PBS sequence (nucleotides 168–173), a
16-mer anti-A loop PNA sequence, ATTTTCCACACTGACA,
was synthesized.
We obtained the 16-mer penetratin (RQIKIWFQNRRM-
KWKK), and 13-mer Tat (GRKKRRQRRRPPQ) peptides from
Bachem Biosciences Inc., King of Prussia, PA. The peptide
sequences bear a cysteine at the N-terminal and the –SH group
of cysteine was activated using a 3-nitro pyridine sulphenyl
(NPYS) group. We used this cysteine for conjugation with PNA
sequences.
Synthesis of PNAPBS–Tat, PNAPBS–Penetratin, PNAA-loop–Tat,
and PNAA-loop–Penetratin
The synthesis and purification of all PNA MTD peptide
conjugates were carried out as described before (Tripathi et al.,
2005). We determined the concentration of the conjugates by
dividing OD at 260 nm by molar extinction coefficient
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for A-loop PNA. We characterized the PNA–peptide conjugates
by matrix-assisted laser desorption ionization time-of-flight
(MALDI-TOF).
Synthesis of fluorescein-labeled PNA
For this purpose, we synthesized individual PNA on solid
support having a cysteine at the N-terminal. An “egl” linker (8-
amino-3, 6-dioxaoctanoic acid) was also attached to the amino
group of N-terminal cysteine to which fluorescein was attached
as described before (Tripathi et al., 2005). The fluorescein-
tagged PNA was kept protected from light and further conju-
gated with MTD peptides.
Preparation of 32P-labeled U5-PBS RNA template
We linearized the pU5-PBS plasmid using Xho-1, then
transcribed it to generate a 250-base-long run-off RNA
transcript of the U5-PBS region, using a T7 RNA polymerase
transcription kit (Roche Biochemicals, Indianapolis, IN). The
RNA transcript was internally labeled using α32P-CTP
(3000 Ci/mmol; Perkin-Elmer Life and Analytical Sciences
(Boston, MA). We purified the run-off transcript by phenol:
chloroform: isoamyl alcohol extraction followed by ethanol
precipitation. We air-dried the RNA and resuspended it in water
pretreated with diethyl pyrocarbonate (DEPC), then stored it at
−70 °C.
Gel mobility shift assay
We incubated an aliquot of internally 32P-labeled U5-PBS
RNA transcript (10 nM) with varying concentrations of PNA or
PNA–peptide conjugates in a binding buffer containing 50 mM
Tris–HCl, pH 8.0, 75 mM KCl, 5 mM MgCl2, 1 mM DTT,
0.01% NP-40, and 500 ng poly r(I-C) in a final volume of 10 μl.
After incubation at room temperature for 30 min, we added 5 μl
of gel loading dye (0.2% bromophenol blue and 12% glycerol)
to each sample. The samples were run (150 V) on an 8% native
polyacrylamide gel using Tris–borate EDTA buffer at room
temperature for 4 h. The gel was subjected to PhosphorImager
analysis (Molecular Dynamics, Sunnyvale, CA).
Evaluation of cellular uptake of fluo-O-PNA–MTD peptide
conjugate by flow cytometry
We used CEM T-cell lymphocytes to study the uptake of
PNA–MTD peptide conjugates. We grew the cells in log phase,
harvested them, washed them with phosphate-buffered saline
and resuspended them in RPMI medium with 2% FCS. We
incubated approximately 0.5×106 cells with fluorescein-labeled
PNA–peptide conjugates for 1 min at 4 °C and 37 °C. The cells
were washed twice with phosphate-buffered saline and resus-
pended in RPMI medium with 2% FCS, then analyzed by flow
cytometry on a Becton Dickinson (San Jose, CA) flow
cytometer. To exclude uptake by dead cells, we did the scanning
in the presence of propidium iodide (1 μg/ml). We did a secondset of experiments by incubating the fluorescein-positive cells in
the presence of 0.01% trypsin in phosphate-buffered saline for
10 min. We washed the cells twice with phosphate-buffered
saline and suspended them in RPMImedium containing 2%FCS
and 1 μg/ml propidium iodide. We evaluated the fluorescence
intensity in the trypsin-treated cells by flow cytometry. Cell
Quest Pro software from Becton Dickinson was used to acquire
and analyze 104 events detected by the FL1 detector
(fluorescein) and excluded by the FL3 detector (propidium
iodide).
Visualization of Cellular uptake of fluo-O-PNA–MTD peptide
conjugate by fluorescence microscopy
CEM cells (1×106) were incubated with 100 nM of flu-
PNAPBS–Penetratin for 30 min and then treated with 0.01%
trypsin as described above. Cells were washed with phosphate
buffer saline and resuspended in 250 μl of cell fixing reagent
(BD Cytofix Buffer, BD Biosciences Pharmingen, San Diego,
CA) for 15 min at room temperature. Subsequently cells were
washed with 1× phosphate-buffered saline containing 0.02%
Tween-20 and 0.5% BSA and then treated with 100 μl (10 μg/
ml) of 4′,6′-diamidino-2-phenylindole (DAPI, Sigma). Cells
were washed again with the same buffer three times and 10 μl of
the cell suspension was put on a glass-slide and covered with a
cover slip. The ZEISS Axiovert 200 M microscope fitted with
an ApoTome imaging system was used for fluorescence
microscopy. All images shown are from a representative axial
plane.
Uptake kinetics of PNA–MTD peptide conjugate
For these experiments, we labeled the Tyr residue of the PNA
moiety of the PNA–MTD peptide conjugate with (125I) using
the chloramine-T labeling kit (MP Biomedical Inc, Irvine, CA)
as described before (Tripathi et al., 2005). The final purified
product was lyophilized, resuspended in deionized water, and
quantified spectrophotometrically by measuring the OD at
260 nm. We adjusted the specific radioactivity by adding cold
unlabeled PNA–MTD peptide conjugates. We harvested CEM
cells grown in log phase and used 0.5×106 cells for each
experiment. We incubated the cells for 30 s with increasing
concentrations of I125-PNA–MTD peptide conjugates and
filtered them on GF-B filters under mild negative pressure.
We washed the cells repeatedly with phosphate-buffered saline
to remove any traces of free unincorporated radiolabeled PNA–
MTD peptide conjugates. The filters were air-dried and counted
in a gamma counter. The [S]0.9/[S]0.1 ratio and cooperativity
index of the substrate at 0.9Vmax and 0.1Vmax were determined
by plotting the uptake versus substrate concentration. Hill
coefficient (nH) was determined from the slope of the Hill plot.
Production and purification of HIV-1 pseudovirions
For production of highly infectious pseudotyped HIV-1
virions, we co-transfected 293T cells with pHIV-1JR-CSF-lucenv(−)
and pVSV-G, using the calcium phosphate transfection system
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1995). The culture supernatants saved at 24, 48, and 72 h after
transfection were pooled and analyzed for p24 antigen using the
ELISA p24 antigen kit (ZeptoMetrix, Buffalo, NY). We isolated
the pseudotyped HIV-1 virions from the culture supernatant by
filtration through a 0.45-μm pore size PVDF membrane
(Millipore, Bedford, MA) then ultracentrifuged them at
70,000×g for 45 min. The viral pellet was resuspended in
complete Dulbecco's medium and stored at −80 °C.
Measurement of luciferase activity
Cells infected with infectious pseudo-HIV-1 virions carrying
the luciferase reporter gene were harvested, washed with
phosphate-buffered saline, and resuspended in 1× passive
lysis buffer (Promega, Madison, WI). The solutions were
gently shaken on a rocker at 25 °C for 15 min and centrifuged.
We placed the lysate on a 96-well plate Fluotrac 200 (Greiner
Labortechnik, Germany) and added 100 μl of luciferase assay
reporter (Promega). We measured the firefly luciferase activity
on a Packard Top Count Luminometer. The total light unit was
normalized by total protein content in the cell lysate. Total
protein was quantified using the DC Protein assay kit (Bio-Rad
Laboratories, Hercules, CA).
Endogenous reverse transcriptase activity of HIV-1 virions
after treatment with PNA–peptide conjugates
We incubated HIV-1 virions (equivalent to 80 pg of p24) with
individual PNA–MTDpeptide conjugates at 250-nM or 500-nM
concentrations for 30 min at 37 °C, then ultracentrifuged the
incubation mixture through 20% sucrose solution (Beckman
Coulter Optima LE-80K ultra, Palo Alto, CA) at 100,000×g for
1 h at 4 °C.We resuspended the virion pellets in disruption buffer
containing 50 mM Tris–HCl, pH 7.8, 10 mMDTT, 66 mMKCl,
0.3 mM EDTA, 0.14% NP-40, and 1 U/μl RNAsin. We
examined an aliquot of the disrupted virions for endogenous
reverse transcription in reverse transcriptase buffer composed of
5 mMMgCl2, 50 mM KCl, 10 mM DTT, 30-μg actinomycin D/
ml, 25 μg BSA/ml, 10 μM of dATP, dGTP and dTTP, and
1.25 μM of dCTP with 5 μCi of α32P-dCTP (3000 Ci/mmol).
The reaction was carried out at 37 °C for 10 min followed by the
addition of more dNTPs (0.5 mM each), then resumed for
another 30 min. The reaction was quenched by the addition of
50 mM of EDTA, followed by phenol–chloroform extraction
and alcohol precipitation. We air-dried the pellet and dissolved it
in formamide gel loading dye. The reverse transcription products
were resolved on 6% polyacrylamide-urea denaturing gel.
Antiviral efficacy of PNA–MTD peptide conjugates
We grew CEM CD4+ lymphocytes 12D7 (Kashanchi et al.,
1994) in RPMI-1640 medium supplemented with 10% fetal calf
serum and 4 mM L-glutamine at 37 °C in 5% CO2 containing
humidified air. We harvested early-mid log phase cells and
washed them with an equal volume of phosphate-buffered saline
without Ca2+ and Mg2+. We incubated approximately 0.5×106cells suspended in 1 ml of RPMI-1640 medium with pseudo-
virions (equivalent to 14 ng of p24) by gentle rocking for 2 h in
presence of respective amounts of PNA–peptide conjugates.
The cells were centrifuged, washed with phosphate-buffered
saline and resuspended in complete RPMI media in a 12-well
plate containing increasing amounts of conjugates (200 nM–
1 μM). After 48 h, the cells were harvested, washed with
phosphate-buffered saline, and lysed in 1× passive lysis buffer
(Promega) with gentle shaking on a rocker for 15 min at room
temperature. We centrifuged the lysed cells at 15,000 rpm for
15 min and assayed an aliquot of the clear lysate for reporter
luciferase activity.
Antiviral efficacy experiments were also carried out using
peripheral blood mononuclear (PBMC) cells. PHA-stimulated
PBMC cells were suspended in complete medium (RPMI 1640,
15% FCS, 5% Interleukin-2, 1%-pen-strep, 2 mM L-glutamine,
2 mg/ml polybrene). For per assay 1×106 cells were used and
incubated with pseudovirions (equivalent to 14 ng of p24) by
gentle rocking for 2 h in presence of respective concentrations of
PNA–peptide conjugates. The cells were then centrifuged and
grown in presence of increasing concentrations of PNAPBS–
Penetratin and left for 7 days (Liu et al., 1998). The assessment
of luciferase activity in the cell lysate was carried out as
discussed above.
Virucidal activity of individual PNA–MTD peptide conjugates
We incubated pseudovirions equivalent to 100 ng of p24 in
complete RPMI medium with increasing amounts of individual
PNA–MTD conjugates, ranging from 0.01 to 1 μM, for 2 h at
37 °C. We separated the treated virions from free conjugates by
ultracentrifugation at 100,000×g for 1 h and used them to infect
CEM T lymphocytes as described earlier. The infected cells
were grown in fresh complete RPMI media for 48 h, harvested,
lysed, and assayed for luciferase activity, also as described.
These experiments were also performed in the presence of
different concentrations (20–100%) of fetal calf serum. The
virion particles were first centrifuged and then resuspended in
different concentration of serum in RPMI medium. Each of the
virion samples containing different serum concentration was
treated with the conjugate and examined for their infectivity in
CEM cells as above.
Calculation of IC50
Using CalcuSyn software, we determined median dose
effects (IC50) for individual PNA–MTD peptide conjugates.
The software, developed by BIOSOFT (Cambridge, UK), is
based on equations developed by Chou (Chou, 1974, 1977)
correlating the “dose” and “effect.” The equation for calculating
median dose, [fa/fu= (D/Dm)
m], takes into account the fraction
affected by dose ( fa) and the fraction unaffected, fu=1− fa
where D is the dose of the drug and Dm is the median dose; m is
an exponent signifying the sigmoidicity of the dose–effect
curve. We include the IC50 values determined by CalcuSyn
software corresponding to the median effective doses with 95%
confidence limits in the results table (Tables 1A and B).
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cellular proliferation
Cellular proliferation of CEM cells in the presence of
PNAPBS–Penetratin conjugate was determined by measuring
the levels of [3H] thymidine incorporated in their nuclei as
described before (Kaushik et al., 2002). Briefly, the CEM cells
in log phase were grown in the presence of varying
concentrations (1, 5 and 10 μM) of PNAPBS–Penetratin and
supplemented with 10 μCi of [methyl-3H] Thymidine/ml
(85 Ci/mmol). The cells were harvested at different time
intervals up to 96 h, harvested, washed with phosphate-buffered
saline and finally resuspended in lysis buffer comprising of 1%
NP-40 in phosphate-buffered saline solution. The nucleic acids
were precipitated by adding cold 10% tricholoroacetic acid. The
precipitated nucleic acids were collected on glass-fiber filter and
washed extensively with cold 10% tricholoroacetic acid and
once with 70% ethanol. The filters were dried, placed in
scintillation vial and counted for radioactivity in a Liquid
Scintillation Counter to assess the extent of radiolabel
incorporation. Protein content in each assay was estimated by
the Bio-Rad DC Protein assay and the results are expressed as
counts per minute per gram of protein.
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